Oxidative stress is a hallmark of numerous airway diseases, contributing to extensive cell and tissue damage.
INTRODUCTION
Asthma is a chronic disease of the airways which is characterized by inflammation, structural cell dysfunction, and excessive airway narrowing. Many of the features of asthma have been linked to reactive oxygen species (ROS) produced endogenously and upon exposure to environmental insults including air pollution, pollens, and smoke (45). ROS cause damage to tissues and cellular components and can act as a potent promoter of proinflammatory signals (42, 60, 61) . Indeed, in airway epithelial cells, ROS enhances IL-8 production and reduces the activity of HDAC2 (26) , a gene which has been linked with steroid refractoriness in asthma (8, 32) . In asthmatic patients, the abundance of ROS in the serum is correlated with the degree of airway hyperresponsiveness (AHR) and acute exacerbations of asthma requiring hospitalization (7, 14) .
ROS are capable of damaging lipid membranes and the lipid-rich mucus lining of the airways resulting in the production of a group of potent pro-inflammatory molecules collectively known as oxidized phospholipids, or OxPC (4) . OxPC are produced from the poly-unsaturated fatty acid tails of phospholipids namely arachidonoyl and linoleoyl to form OxPAPC and OxPLPC respectively (17) . In disease, OxPC promote the induction of atherogenic pathways in endothelial cells (19, 30) , dose dependently disrupt endothelial barrier function and induce adherens junction dissociation (3) . OxPC are also associated with inflammatory pain, mediated by transient receptor potential channels TRPA1 and TRPV1 (35) . In the lung, OxPC have been identified in mice and humans following infection with influenza and Mycobacterium (9, 31, 50) and in response to inhaled allergen challenge in asthma (27, 36) . Some literature suggests that low doses of OxPC can act as inhibitors of toll-like receptor (TLR) signaling (11) however most research agrees they act as mediators of inflammation and disease (18, 39) . In cultured airway smooth muscle cells, OxPC promote inflammation characterized by IL-6, IL-8, GM-CSF, and the production of pro-inflammatory lipid mediators (40, 41) .
The airway epithelial cell plays an important role in protecting the underlying tissue from environmental irritants and coordinating inflammatory responses against microbes, and it is well established that dysfunction in the airway epithelium is an important factor asthma pathogenesis (24) . With the recent identification of OxPC in the lungs of people with asthma and their well-established role in disrupting endothelial cell function in the vessels, we sought to establish their role in asthma pathogenesis through their ability to disrupt airway epithelial cell function. This manuscript is the first to show that OxPC promote airway epithelial cell dysfunction by disrupting their ability to form a protective barrier, impairing their self-repair capacity, and promoting ongoing oxidative stress evidenced by the production of additional ROS and lipid peroxides.
RESULTS

OxPC induce cell stress and loss of viability in airway epithelial cells
OxPC treatment resulted in dose-dependent cell stress in each cell type tested ( Fig 1A) . However, the magnitude of the effect was variable across our epithelial cells with strong responses at low doses in BEAS-2B (p<0.0001, n=5), moderate responses in Calu-3 (p<0.0001, n=5), and weak responses in nHBE (p<0.0001, n=5) and ALI-nHBE (p=0.0257, n=3). High levels of cell stress were associated with cell death ( Fig 1B) ; reduced cell viability was evident in BEAS-2B at OxPC doses as low as 10µg/mL (p<0.0001, n=5), and doses of 160 µg/mL were cytotoxic in Calu-3 (p<0.0001, n=4). No loss of viability was detected in nHBE (p=0.2204, n=5). Statistical significance was achieved in ALI-nHBE (p=0.0438, n=3), however the magnitude of any effect was extremely small with no obvious dose dependence and no significance in post-tests. The non-oxidizable PSPC caused no quantitative or qualitative changes in this experiment, or in any subsequent experiment.
Qualitatively, there was a visible loss of confluence associated with low viability in BEAS-2B and Calu-3 cells; a portion of cells would detach from their neighbours and 'ball-up' before eventually losing substrate adherence.
Floating cells did not survive when re-plated in OxPC-free medium (data not shown).
OxPC reversibly impair epithelial barrier function and wound healing
OxPC exposure at 80 and 160 µg/mL resulted in significant barrier impairment in Calu-3 cells, as measured by both paracellular permeability (Fig 2A; p<0 .0001, n=5) and TEER assays ( Fig 2B; interaction p<0.0001, time p=0.0032, OxPC p<0.0001, n=4). Surprisingly, the 40 µg/mL dose trends towards barrier reinforcement by TEER but this effect was not significant. For ALI-nHBE, OxPC treatment did not cause any difference in permeability ( Fig 2C; p=0 .5510, n=3), and only a modest impairment of TEER ( Fig 2D; interaction p=0.9909, time p=0.0007, OxPC p=0.0232, n=3). The effect on TEER appeared dose dependent, but no significant differences were detectable in post-tests.
Combining OxPC with a physical scratch revealed that the simultaneous 'two hits' could cause additional barrier dysfunction in Calu-3 cells ( Fig 3A; interaction p<0.0001, time p<0.0001, OxPC p<0.0001, n≥4). The 80 and 160 µg/mL groups displayed a profound failure of wound healing from 24 hours. Moreover, combining OxPC at 40 µg/mL with a scratch resulted in a significant delay in wound healing at 24-48 hours, in stark contrast to OxPC treatment alone. To further demonstrate OxPC-induced-dysfunction is dependent on the overall degree of cell stress and is not necessarily permanent, scratched Calu-3 were exposed to 80 or 160 µg/mL OxPC for 24 or 72 hours, before the OxPC were washed off, and TEER re-measured after 24 hours. OxPC 80 µg/mL treated cells could partially recover barrier function ( Fig 3B; p=0 .0079, n≥4) and the recovery was more complete with shorter exposure times. A single well of 160 µg/mL exposed cells saw a full recovery of TEER, but this maximal dose was otherwise terminal to barrier function.
In ALI-nHBE, OxPC at 160 µg/mL caused a modest but highly significant impairment of wound healing at 48 hours, with dose-dependent dysfunction persisting until 7 days ( Fig 3C; interaction p=0.8773, time p<0.0001, OxPC p<0.0001). This indicates that combining OxPC with an additional stress can cause barrier dysfunction in otherwise resilient cells.
OxPC reversibly inhibit DNA synthesis
Airway epithelial wound healing involves an initial migratory phase followed by increased proliferation at the wounded edge (58), thus we histologically assessed DNA synthesis to better understand wound healing dynamics ( Fig 4) . As expected, scratched cultures exhibit increased DNA synthesis compared with untreated controls, with qualitatively higher synthetic activity at the leading edge. In contrast, a submaximal 80 µg/mL OxPC dose results in a dramatic decrease in DNA synthesis at 24 hours (p<0.0001, n=4) and, qualitatively, the cells do not migrate to close the wound. DNA synthesis returns to control levels if OxPC are left on the cells for 48 hours but experiences a dramatic rebound if OxPC are washed off the cells, without immediate wound closure. These results are entirely consistent with the barrier function results following both scratch and wash protocols.
OxPC do not regulate the mRNA abundance of epithelial phenotype markers
To confirm that barrier dysfunction was not modulated by epithelial barrier phenotype, the relative mRNA abundance of three key phenotypic markers was measured after OxPC exposure ( Fig 5) . Neither e-cadherin (CDH1, p=0.4295, n=4) nor vimentin (VIM, p=0.4362, n=4) mRNA levels were altered by OxPC, suggesting maintenance of epithelial barrier phenotype and no acquisition of mesenchymal features. Zonula occludens 1 (TJP1) mRNA levels were significantly different across the groups in the ANOVA statistic (p=0.0069, n=4), however there was no linear dose dependence and post-tests revealed no individual group differences. The small magnitude of the changes was below the realistic statistical limit of detection for RT-qPCR (54) suggesting that statistical differences in TJP1 levels have low biological relevance.
OxPC induce general ROS accumulation
The cell migration and proliferation required for wound healing are metabolically intensive. To assess whether OxPC induce oxidative stress consistent with pathological respiration, we examined the effect of OxPC on ROS accumulation. OxPC rapidly induced general ROS accumulation in a time-and dose-dependent manner ( Fig 6A- B; p<0.0001, n=7). To put these results in context of known disease-linked modulators, we performed separate experiments exposing cells to a maximal dose of HDM. General ROS accumulation was significantly elevated in response to HDM (p=0.0314, n=3), although the magnitude was markedly lower than a maximal OxPC dose.
To ascertain the specific cellular source of ROS, we assessed the accumulation of mitochondrial and cytosolic superoxide. Mitochondrial superoxide was not significantly altered by OxPC treatment (Fig 6C; p=0 .3730, n=5), and no qualitative histological difference was apparent when compared with the brightly stained positive control ( Fig 6D) . Cytosolic superoxide reached statistical significance ( Fig 6E; p=0 .0227, n=5) however there was no obvious dose-dependence, post-tests were not significant, and the overall magnitude of any OxPC-related response was considerably lower than the corresponding positive control. Moreover, imaging of the fluorescent signal shows no qualitative difference between the control and maximal dose of OxPC relative to the much brighter positive control ( Fig 6F) . This indicates that cytoplasmic superoxide accumulation is unlikely to be biologically significant during OxPC exposure.
Receptor blockade does not mitigate OxPC-induced ROS accumulation
In other cell types, the negative effects of OxPC are associated with specific receptor-mediated pathways. To determine whether these pathways are responsible for our results in epithelial cells, Calu-3 were exposed to a maximal 160 µg/mL OxPC dose in the presence of putative OxPC receptor blockers (Fig 7) . For each of the PAFR (WEB-2086; p=0.1179, n=3), EP2 (PF-04418948; p =0.5317, n=3), CD36 (SSO; p=0.7256, n=4) and TLR2/4 receptors (SsnB; p=0.1664, n=3), blocking agents could not inhibit general ROS accumulation. In contrast, the antioxidant NAC inhibited ROS in a dose-dependent manner, being able to completely reverse ROS accumulation at 10 mM (p=0.0004, n=3).
OxPC induce additional lipid peroxidation
To determine whether ROS formation could induce ongoing cellular dysfunction, we assessed lipid peroxide generation. Similar to general ROS accumulation, lipid peroxides began accumulating rapidly after OxPC addition, with higher doses surpassing the level of lipid peroxides produced by the positive control cumene-OOH within 60 minutes ( Fig 8A) . At the 2-hour endpoint, all OxPC doses were significantly higher than control ( Fig 8B; p<0 .0001, n=4), with a very strong dose dependency. In separate experiments, HDM was assessed for its ability to induce lipid peroxidation. The effect of HDM approached significance (p=0.0522, n=3), but the magnitude of the change was smaller than even the lowest dose of OxPC. Surprisingly, 10 mM NAC was only able to partially reverse the accumulation of lipid peroxides ( Fig 8C; p=0 .0001, n=7).
To confirm these results and determine whether lipid peroxides were localised to any particular cellular compartment, lipid peroxidation was assessed by an alternative histological technique. OxPC induced a qualitative increase in lipid peroxides that were diffuse across the cell membrane and cytoplasm. There was no obvious segregation or punctate patterning that would indicate isolation to any specific organelle ( Fig 8D) .
DISCUSSION
Epithelial dysfunction and disease relevance
The airway epithelial barrier is the gateway to the lung and dysfunction of this barrier at a cellular level is associated with both asthma pathogenesis (25) and asthma severity (33) . For this reason, we sought to explore the ability of OxPC to induce epithelial barrier dysfunction in the context of asthma. Our results indicate that OxPC are capable of disrupting normal airway epithelial cell function and promoting pathologic features similar to those seen in the airways of people with asthma. This includes a loss of barrier integrity (21), impaired wound healing capacity (47) , and further production of reactive oxygen species (12) .
Wounding the epithelial layer increased the barrier-disrupting potency of OxPC, most notably in differentiated primary airway epithelial cells. This suggests that OxPC could be important in potentiating the negative effects of allergenic insults or other stressors in diseased airways. In this regard, exposing epithelial cells to HDM resulted in an increase in ROS that was considerably smaller than the level induced by low doses of OxPC.
Additionally, OxPC exposure was capable of stimulating further production of lipid peroxides indicating the potential for a self-propagating cycle that starts with allergen exposure. Interestingly, the negative effects of OxPC could be reversed following their removal suggesting that OxPC do not inherently cause permanent cell damage or irrecoverable activation of cell death pathways. Therefore, OxPC are potentially important molecules in the pathogenesis of asthma and interventions aimed at limiting their production or promoting their removal could be novel therapeutic options for this disease.
OxPC have been identified as a bioactive lipid molecule that have relevance to many chronic human diseases.
In atherosclerosis, blocking the action of OxPC with the antibody E06 in mice reduced the amount of atherosclerosis and aortic valve calcifications (39) . Following renal ischemia reperfusion injury in rats, there was a significant elevation in 55 OxPC species which correlated with the severity of the injury (46) . Recently, members of our team have identified OxPC in the airways of mice and humans following allergen challenge and these were shown to be correlated with PC 20 following allergen challenge in people. In airway smooth muscle cells, OxPC promote an inflammatory phenotype, characterized by secretion of IL-6, IL-8, GM-CSF, the production of eicosanoids, and were controlled by signaling events through protein kinase C. Developing treatments that target the actions of OxPCs in the airways could offer us a better way to ameliorate the effects of oxidative stress in asthma, therefore augmenting our current treatment regimes.
Mechanisms of oxidative stress and lipid peroxidation
OxPC have been linked to signaling events involving PAFR, EP2, CD36 and TLR2/4 (29, 52) . We were unable to show that any of these receptors were involved in mediating accumulation of ROS in response to OxPC in this study. Only pre-incubation with antioxidant NAC was able to reduce the cellular accumulation of ROS in response to OxPC. NAC operates as a cysteine source for the production of glutathione (44) and it is known the glutathione anti-oxidant system is finely tuned for controlling cellular levels of lipid peroxides (56) . In children with severe asthma, the oxidized glutathione levels are significantly elevated and reduced glutathione levels significantly repressed (16) indicating an elevated level of oxidative stress. Additionally, there exists single nucleotide polymorphisms (SNPs) in some of the genes for the glutathione-s-transferase enzymes that are associated with increased asthma risk (28, 48) . Disequilibrium in the glutathione system could thus indicate a diminished ability to detoxify OxPC in the airways and make people with asthma particularly susceptible to the effects of OxPC. An alternative antioxidant mechanism for NAC involves triggering intracellular sulfane sulfur production which has antioxidant and cytoprotective functions (13) . In this regard, treatments that increase endogenous production of sulfane sulfur could be useful in decreasing the antioxidant burden in asthma, specifically related to OxPC.
Despite the theoretical benefits of antioxidant treatments for asthma, results from animal and patient studies are mixed. With the exception of specific vitamin E isoforms that may specifically detoxify lipid peroxides (23, 38) , dietary antioxidant supplementation seems to provide minimal benefit beyond a decrease in exhaled FeNO (1, 37, 49, 55) . This may be consistent with our observations that NAC was unable to completely reverse lipid peroxidation, and that neither mitochondrial nor cytosolic superoxide are credible sources for the large magnitude of the dysfunction we observed. This raises the possibility that the primary pathology induced by OxPC is specifically associated with lipid metabolism. Xenobiotic metabolism involving cytochrome P450, lipoxygenase and cyclooxygenase are well known to produce lipid peroxide by-products and these reactions can be self-propagating in the presence of oxygen (2) . Alternatively, OxPC could derange a wide range of mitochondrial lipid metabolism enzymes without necessarily producing a detectable superoxide intermediate (34) . Metabolomic analysis of OxPC affected cells will be required to precisely determine which lipid peroxides are produced, the pathways and enzymes that may be responsible, and how this process could be mitigated.
Differential cell responses
Intriguingly, we found significant differences in the responsiveness of different epithelial cells to OxPC exposure. This may represent a culturing artifact of undifferentiated epithelial cells and cell lines but may also highlight how OxPC may become disease relevant. Airway epithelium from people with asthma exhibits an elevated number of basal cells and a reduction in the number of cells expressing E-cadherin (20) suggesting a more immature phenotype. In this regard, airway epithelium from asthma may be more susceptible to the effects of OxPC due to its relatively undifferentiated state. Alternatively, commercial supplements for culturing primary epithelial cells in ALI contain hydrocortisone which has been shown to inhibit the inflammatory response of cultured epithelial cells (15) and support mucociliary transport in cells (59) . Importantly, glucocorticoids have been shown to increase the activity of antioxidant enzymes in asthma (10) . We did not remove hydrocortisone from the media prior to experimentation which may have conferred some protection and only allowed us to observe negative effects on barrier function when OxPC was combined with a scratch.
Finally, OxPC had a significant impact on DNA synthesis in our experiments suggesting that they may inhibit proliferation. Primary cells are relatively quiescent compared with the cell lines used in this study perhaps indicating that proliferating cells, or those that have a high metabolic requirement, are particularly susceptible to OxPC exposure. It will therefore be important to study how prolonged OxPC treatment alters the growth and differentiation trajectory of primary epithelial cells, to determine the effect on mucociliary phenotype and barrier function.
Summary
We have demonstrated that OxPC induce profound dose-dependent cellular dysfunction that may potentiate other stressors to manifest as impaired epithelial barrier function in diseased airways. Future work will need to ascertain whether the cellular dysfunction we have observed is a product of the combination and total quantity of OxPC applied, or can be attributable a single OxPC species operating through a specific mechanism.
Understanding the role of individual OxPC in causing epithelial cell dysfunction will help us to identify potential treatment options that protect the cell or 'mop-up' OxPC in a more specific manner than NAC and more completely prevent lipid peroxide accumulation. Finally, by using mice that express the anti-OxPC antibody (E06), and determining whether OxPC can augment the pathology associated with HDM exposure, it will be possible to ascertain whether OxPC are sufficient and necessary for the pathogenesis of airway disease.
METHODS
Cell Culture
Calu-3 human airway epithelial cells were purchased from ATTC (HTB-55). Cells were propagated in DMEM/F-12 (Gibco 11330057) supplemented with 10% heat inactivated fetal bovine serum (FBS) (Gibco 12483020) and Normal human bronchial epithelial cells were purchased from Lonza (CC-2540S, lot # 493462) and grown in PneumaCult™-Ex Plus Medium (Stemcell Technologies 05040). Cells at passage 2-3 were trypsinized and reseeded onto 12-well plates (nHBE) or Transwells (ALI-nHBE) at a density of 1×10 5 cells/cm 2 and maintained in PneumaCult™-Ex Plus for 3-4 days. ALI-nHBE cells were then transferred to fully supplemented PneumaCult™-ALI Medium, exposed to an air-liquid interface, and maintained for ≥3 weeks for mucociliary differentiation, confirmed by the presence of mucus, ciliary activity, and establishment of epithelial barrier function (>500 Ω.cm 2 ).
BEAS-2B-GRE cells [gift from
Dr. Rob Newton, previously described previously in (6) ] were propagated in DMEM/F-12 supplemented with 10% FBS and 100 µg/mL G418, and seeded at a density of 3×10 3 cells/cm 2 in 12-well plates. Cells were grown until approximately 80% confluent then serum deprived for 24 hours in DMEM/F12 with 1% ITS.
Generation and Administration of Oxidised Lipids
OxPC were generated by exposing PAPC (1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids 850459C) to room air for 4 days, during which PAPC visibly changed from a white to yellow paste. The non-oxidizable negative control PSPC (1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids 850456C) was exposed to the same conditions and did not exhibit any visible changes. Treated OxPC/PSPC were resuspended in chloroform:methanol (2:1) at 1mg/mL and stored at -20 o C under nitrogen gas to prevent further oxidation. The oxidation state of both lipid preparations was confirmed by LC/MS/MS (53) .
OxPC and PSPC were prepared for dosing by aliquoting an appropriate volume of lipid solution and evaporating the chloroform:methanol under a stream of sterile nitrogen. The remaining lipid was immediately resuspended in warm media or buffer as appropriate and added to the cells (Calu-3 on Transwells: 1 mL apical chamber, 0.5 mL basolateral chamber; Calu-3, nHBE and BEAS-2B-GRE in 12-well plates: 1 mL; ALI-nHBE on Transwells, 1 mL basolateral chamber, 75 µL apical chamber). For exposure times exceeding 3 days, cells were re-dosed with OxPC/PSPC in fresh media every 3-4 days.
Cell Stress and Viability
Cell stress was assessed by LDH release using the Roche Cytotoxicity Detection Kit (Roche 11644793001) in cells treated with OxPC (0-160 µg/mL) or PSPC (160 µg/mL) for 24 hours. Culture media was collected, gently centrifuged (150 × RCF for 4 minutes) and combined with the kit reagent for 10 min before absorbance readings were taken at 490 nm. LDH release was expressed as the percentage of LDH activity in the media relative to untreated control cells lysed with 2% triton X-100. 
mRNA abundance
The mRNA abundance for epithelial phenotype markers was assessed by RT-qPCR. Calu-3 were treated with OxPC or PSPC for 18 hours before total RNA was isolated by the Ambion Purelink RNA Mini Kit (Thermo Fisher 12183025) before RNA concentration and purity were assessed by A 260 :A 280 spectrophotometry. Reverse transcription was performed with 1 µg total RNA using iScript Reverse Transcription Supermix for RT-qPCR (Biorad 170-8841). cDNA equivalent to 20 ng of total RNA was then amplified in duplicate using SsoAdvanced Universal SYBR Green Supermix (Biorad 172-5274) and 300 nM of the appropriate primers ( software, and mean reaction efficiency (E) was determined using LinRegPCR 2017.0 (43) . Relative mRNA abundance was calculated using efficiency-corrected ΔCt (E ΔCt ) divided by a normalizing factor (NF) derived from the geometric mean of E ΔCt for two stable housekeeping genes (22, 51) . The final data was scaled such that untreated control condition presented a mean result of 1 AU.
Oxidative Stress
The capacity of OxPC and house dust mite extract (HDM, Greer XPB82D3A2.5) to induce the accumulation of general cytosolic ROS, cytosolic superoxide and mitochondrial superoxide in Calu-3 were assessed by dichlorofluorescein (DCF), dihydroethidium (DHE) and MitoSOX assays respectively. For DCF assays, serum- The sub-cellular location of lipid peroxides was determined with the Click-iT Lipid Peroxidation Imaging Kit (Thermo Fisher C10446). Calu-3 cells were simultaneously loaded with 50 µM linoleamide alkyne (LAA) and treated with OxPC in HBSS for 2 hours. Cells were then washed with PBS, fixed in 4% PFA for 15 minutes then permeabilized in 4% PFA with 0.5% triton X-100. After 3 washes in PBS cells were blocked with 1% BSA for 30 minutes and LAA fluorescent labelling was performed per the manufacturer's instructions. Cells were then counterstained, mounted and imaged as described above.
Data Analysis and Statistics
All numerical data are presented as mean ± standard error. Each 'n' value represents a fully independent experiment created from a separate flask of stock cells. Statistical tests were performed with the GraphPad Under static conditions, barrier function was impaired by OxPC in a dose-dependent and cell-specific manner. OxPC treatment potentiates barrier dysfunction after a scratch. In Calu-3 cells, OxPC at 40 µg/mL significantly delayed wound healing (contrast with the lack of defect at 40 µg/mL in Fig 2B) with profound dysfunction at 80-160 µg/mL (A; interaction p<0.0001, time p<0.0001, OxPC p<0.0001, n≥4). However, barrier function could partially recover in the 80 µg/mL condition if OxPC are rapidly washed off (B; p=0.0079n≥4). Scratched ALI-nHBE cultures display defective wound healing in the OxPC 160 µg/mL group (C; interaction p=0.8773, time p<0.0001, OxPC p<0.0001) that is not evident in static cultures (contrast with the lack of defect at 160 µg/mL in Fig 2D) . * represents significant difference from the 0 µg/mL OxPC control condition (wound healing) or between conditions (washout recovery).
Figure 4.
DNA synthesis in Calu-3 cells is upregulated on the leading edge after a scratch, but this is significantly inhibited by 80 µg/mL OxPC (p<0.0001, n=4). DNA synthesis recovers if OxPC are washed off, but without immediate wound closure. * represents significant difference from the 0 µg/mL OxPC control condition. Scale bar is 100 µm.
Figure 5.
Markers for epithelial and barrier phenotype are not appreciably regulated by OxPC in Calu-3 cells. The mRNA abundance of CDH1 (p=0.4295, n=4) and VIM (p=0.4362, n=4) were not significantly altered after OxPC treatment. While statistical significance was detected for TJP1 mRNA levels (p=0.0069, n=4), the small magnitude of the changes and lack of dose dependency makes it unlikely that modulation of this gene is responsible for the observed barrier dysfunction.
Figure 6.
OxPC induce time-(A) and dose-dependent (B) general ROS accumulation in Calu-3 cells (p<0.0001, n=7). HDM is also capable of inducing ROS accumulation (p=0.0314, n=3), but with a much smaller magnitude.
Mitochondrial (C-D; p=0.3730, n=5) and cytosolic (E-F; p=0.0227, n=5) superoxide are only marginally influenced by OxPC, with no obvious dose-dependence and significantly lower signal than their respective positive controls. * represents significant difference from the 0 µg/mL OxPC control condition. Scale bar is 100 µm.
Figure 7.
General ROS accumulation induced by OxPC could be abrogated by the antioxidant NAC (p=0.0004, n=3).
However, inhibitors of established OxPC receptors PAFR (WEB-2086; p=0.1179, n=3), EP2 (PF-04418948; p =0.5317, n=3), CD36 (SSO; p=0.7256, n=4) and TLR2/4 (SsnB; p=0.1664, n=3) each had no effect. * represents significant difference (i.e., inhibition) from the OxPC 160 µg/mL condition. Untreated Controls are shown for reference in each graph but are not included in the statistics.
Figure 8.
OxPC induce time-(A) and dose-dependent (B) generation of lipid peroxides in Calu-3 cells (p<0.0001, n=4). The effect of HDM was modest in comparison and not statistically significant (p=0.0522, n=3). In contrast to general ROS, 10 mM NAC could only partially reverse lipid peroxidation (C; p=0.0001, n=7). Assessing lipid peroxidation by an alternative histological technique (D) confirms significant accumulation that did not appear to be localised to any specific cell membrane or organelle. * represents significant difference from the 0 µg/mL OxPC control condition (B) and from the OxPC 160 µg/mL condition (C). Scale bar is 100 µm.
